论文部分内容阅读
目的研究薯蓣皂苷元衍生物在体外的抗肿瘤活性。方法采用MTT法对人恶性黑色素瘤细胞A375、人肺腺癌细胞A549、人肝癌细胞HepG-2及人慢性髓原白血病细胞株K562进行体外抗肿瘤活性试验。结果薯蓣皂苷元衍生物对4个肿瘤细胞株A375、A549、K562、HepG-2具有不同程度的抗肿瘤活性。结论绝大部分薯蓣皂苷元衍生物对4个肿瘤细胞株有较好的抗肿瘤活性,IC50值都低于30μmol.L-1。化合物22对细胞株A375的IC50=4.48μmol.L-1,化合物9、10对细胞株K562的IC50分别为2.51、2.38μmol.L-1;显示其抗肿瘤活性与对照化合物1-(3β-薯蓣皂苷元)-3-苄基咪唑溴盐相当。
Objective To study the antitumor activity of diosgenin derivatives in vitro. Methods The anti-tumor activity of human malignant melanoma A375, human lung adenocarcinoma A549, human hepatocellular carcinoma HepG-2 and human chronic myeloid leukemia K562 were tested by MTT assay. Results Diosgenin derivatives had different antitumor activity against four tumor cell lines, such as A375, A549, K562 and HepG-2. Conclusions Most of the diosgenin derivatives have good anti-tumor activity against four tumor cell lines with IC50 values lower than 30 μmol.L-1. The IC50 of compound 22 to cell line A375 was 4.48 μmol·L-1, and the IC50s of compound 9 and 10 to cell line K562 were 2.51 and 2.38 μmol·L-1, respectively. The antitumor activity of compound 9 and control compound 1- (3β- Diosgenin) -3-benzyl imidazolium bromide equivalent.